178 related articles for article (PubMed ID: 37466211)
1. Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in.
Gelfand AA; Allen IE; Grimes B; Irwin S; Qubty W; Greene K; Waung M; Powers SW; Szperka CL
Headache; 2023 Oct; 63(9):1314-1326. PubMed ID: 37466211
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
[TBL] [Abstract][Full Text] [Related]
3. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxins for the prevention of migraine in adults.
Herd CP; Tomlinson CL; Rick C; Scotton WJ; Edwards J; Ives N; Clarke CE; Sinclair A
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD011616. PubMed ID: 29939406
[TBL] [Abstract][Full Text] [Related]
7. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial.
Winner P; Pearlman EM; Linder SL; Jordan DM; Fisher AC; Hulihan J;
Headache; 2005; 45(10):1304-12. PubMed ID: 16324162
[TBL] [Abstract][Full Text] [Related]
8. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
9. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
[TBL] [Abstract][Full Text] [Related]
12. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial.
Tepper SJ; Rabany L; Cowan RP; Smith TR; Grosberg BM; Torphy BD; Harris D; Vizel M; Ironi A; Stark-Inbar A; Blumenfeld AM
Headache; 2023 Mar; 63(3):377-389. PubMed ID: 36704988
[TBL] [Abstract][Full Text] [Related]
13. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention.
Gonçalves AL; Martini Ferreira A; Ribeiro RT; Zukerman E; Cipolla-Neto J; Peres MF
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1127-32. PubMed ID: 27165014
[TBL] [Abstract][Full Text] [Related]
15. Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study.
Chowdhury D; Tomar A; Deorari V; Duggal A; Krishnan A; Koul A
Cephalalgia; 2023 Feb; 43(2):3331024221143541. PubMed ID: 36739512
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.
Winner PK; Kabbouche M; Yonker M; Wangsadipura V; Lum A; Brin MF
Headache; 2020 Mar; 60(3):564-575. PubMed ID: 32037549
[TBL] [Abstract][Full Text] [Related]
17. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
[TBL] [Abstract][Full Text] [Related]
18. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial.
Wang F; Van Den Eeden SK; Ackerson LM; Salk SE; Reince RH; Elin RJ
Headache; 2003 Jun; 43(6):601-10. PubMed ID: 12786918
[TBL] [Abstract][Full Text] [Related]
19. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]